Class Action Lawsuit Filed Against ImmunityBio for Alleged Securities Fraud

A securities fraud class action lawsuit has been filed against ImmunityBio, Inc. (NASDAQ: IBRX). The lawsuit, captioned Douglas v. , Case No. 2:26-cv-03261, is pending in the United States District Court for the Central District of California.

It targets investors who purchased or acquired ImmunityBio securities between January 19, 2026, and March 24, 2026, inclusive. The lawsuit alleges material misstatements and omissions concerning ImmunityBio's lead biologic product, Anktiva. Anktiva is a biologic product developed by ImmunityBio for potential medical applications.

The allegations center on disclosures related to this product during the class period. Investors affected by the lawsuit have until May 26, 2026, to file motions for appointment as lead plaintiff. The lead plaintiff represents the class in directing the litigation.

Background on ImmunityBio and Anktiva ImmunityBio, Inc.

is a biotechnology company listed on the NASDAQ exchange under the ticker IBRX. The company focuses on developing immunotherapies, including Anktiva, which is its lead biologic product. Anktiva has been the subject of regulatory reviews and approvals in prior years, though specific details from the class period are under dispute in the lawsuit.

The class action arises from investor losses potentially linked to the alleged misstatements. Securities fraud lawsuits of this nature seek to recover damages for affected shareholders. The case is in its early stages, with no rulings on the merits yet issued.

Next Steps for Investors Kessler Topaz Meltzer & Check, LLP, a securities litigation law firm based in Radnor, Pennsylvania, announced the filing.

The firm encourages affected investors to contact them for information on recovery options. Contact details include attorney Jonathan Naji at (484) 270-1453 or via email at [email protected]. The litigation process will involve discovery, motions, and potentially a trial if no settlement is reached.

Investors do not need to participate to benefit from any recovery, but the lead plaintiff plays a key role. Further developments will depend on court proceedings in the Central District of California.